Evidence map›Paper›PMID 20836852›Full record

ArticleMolecular cancer2010

Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase.

Susmita Mondal, Chandan Mandal, Rajender Sangwan, Sarmila Chandra, Chitra Mandal

Expression of concernOpen access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 94 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Frontiers in pharmacology · 2024
    Article
  6. Integrative Hematology: State of the Art.International journal of molecular sciences · 2023
    Review
  7. Review
  8. Pharmaceutics · 2022
    Review
  9. Ceramide Transfer Protein (CERT): An Overlooked Molecular Player in Cancer.International journal of molecular sciences · 2021
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. A new insight into identification of in silico analysis of natural compounds targeting GPR120.Network modeling and analysis in health informatics and bioinformatics · 2018
    Article
  17. Article
  18. Alcoholic Fractions F5 and F6 fromFrontiers in medicine · 2017
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Susmita MondalInfectious diseases and immunology Division, Indian Institute of Chemical Biology, A Unit of Council of Scientific and Industrial Research, Govt, of India; 4, Raja S, C, Mullick Road, Kolkata 700032, India. cmandal@iicb.res.in.
Chandan Mandal
Rajender Sangwan
Sarmila Chandra
Chitra Mandal
Indian Institute of Chemical Biology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCeramide is an important second messenger that has diverse cellular and biological effect. It is a specific and potent inducer of apoptosis and suppressor of cell growth. In leukemia, chemoresistance generally developed due to deregulated ceramide metabolism. In combinatorial treatment strategies of leukemia, few components have the capability to increases ceramide production. Manipulation in ceramide production by physiological and pharmacological modulators therefore will give additive effect in leukemia chemotherapy.

resultsHere, we show that Withanolide D (C4β-C5β,C6β-epoxy-1-oxo-,20β, dihydroxy-20S,22R-witha-2,24-dienolide; WithaD), a pure herbal compound isolated from Withania somnifera could effectively induces apoptosis in a dose and time dependant manner both in myeloid (K562) and lymphoid (MOLT-4) cells being nontoxic to normal lymphocytes and control proliferative cells. WithaD potentially augment ceramide production in these cells. Downstream of ceramide, WithaD acted on MKK group of proteins and significantly increased JNK and p38MAPK phosphorylation. Pharmacological inhibition of p38MAPK and JNK proves their cooperative action on WithaD-induced cell death. Dissecting the cause of ceramide production, we found activation of neutral sphingomyelinase and showed neutral-sphingomyelinase 2 (N-SMase 2) is a critical mediator of WithaD-induced apoptosis. Knockdown of N-SMase 2 by siRNA and inhibitor of N-SMase (GW4869) significantly reduced WithaD-induced ceramide generation and phosphorylation of MKK4 and MKK3/6, whereas phosphorylation of MKK7 was moderately regulated in leukemic cells. Also, both by silencing of N-SMase 2 and/or blocking by GW4869 protects these cells from WithaD-mediated death and suppressed apoptosis, whereas Fumonisin B1, an inhibitor of ceramide synthase, did not have any effect. Additionally, WithaD effectively induced apoptosis in freshly isolated lymphoblasts from patients and the potent cell killing activity was through JNK and p38MAPK activation.

conclusionOur results demonstrate that WithaD enhance the ceramide accumulation by activating N-SMase 2, modulate phosphorylation of the JNK and p38MAPK and induced apoptosis in both myeloid and lymphoid cells along with primary cells derived from leukemia patients. Taken together, this pure herbal compound (WithaD) may consider as a potential alternative tool with additive effects in conjunction with traditional chemotherapeutic treatment, thereby accelerate the process of conventional drug development.

Indexed as

Aniline CompoundsApoptosisBenzylidene CompoundsBlotting, WesternCell Line, TumorCeramidesFlow CytometryHumansJNK Mitogen-Activated Protein KinasesLeukemiaMAP Kinase Kinase 3MAP Kinase Kinase 4MAP Kinase Kinase 6MAP Kinase Kinase 7Microscopy, Electron, Scanningp38 Mitogen-Activated Protein KinasesAniline CompoundsBenzylidene CompoundsCeramidesGW 4869JNK Mitogen-Activated Protein KinasesMAP2K3 protein, humanMAP2K4 protein, humanMAP2K6 protein, humanMAP2K7 protein, humanMAP Kinase Kinase 3MAP Kinase Kinase 4MAP Kinase Kinase 6MAP Kinase Kinase 7p38 Mitogen-Activated Protein KinasesSphingomyelin Phosphodiesterasewithanolide DWithanolides

Identifiers

PMID20836852
PMCPMC2949798
OpenAlexW2143182558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.